By Allissa Wickham ( December 11, 2014, 7:39 PM EST) -- AstraZeneca AB and three generic-drug producers asked the First Circuit on Wednesday to dismiss their bid to nix class certification in a suit over alleged pay-for-delay deals regarding the heartburn drug Nexium, just five days after a jury handed a victory to the pharmaceutical giant in the lower part of the case....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.